# RGNT — Regentis Biomaterials Ltd · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** RGNT  
**Sources:** 1  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-rgnt-regentis-biomaterials-ltd-catalysts-narrative-risks-10519

---

# Regentis Biomaterials Ltd. (NYSE American: RGNT) — as of 2026-11-01

**Note on sourcing:** The primary company-specific material available comes from a single press release [[1]](https://markets.businessinsider.com/news/currencies/regentis-biomaterials-nyse-american-rgnt-to-present-at-2026-thinkequity-conference-on-oct-15-1036617312), which should be read critically, as it was a **paid marketing engagement** — IBN (IBN.ai) disclosed it receives $30,000 per quarter for up to 180 days of coverage of RGNT [[1]](https://markets.businessinsider.com/news/currencies/regentis-biomaterials-nyse-american-rgnt-to-present-at-2026-thinkequity-conference-on-oct-15-1036617312). Company claims (clinical, commercial, market sizing) are therefore promotional in origin and are corroborated below where the source itself states them. Background snapshots (market cap, sector) are from internal point-in-time records, not independently cited here.

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-rgnt-regentis-biomaterials-ltd-catalysts-narrative-risks-10519 (free to sign up)._